Treatment of cancer during pregnancy with monoclonal antibodies: A real challenge

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 821-826

  Azim Jr , Hatem A ^a   Azim, Hamdy ^b   Peccatori, Fedro A ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b CAIRO UNIVERSITY   (Egypt)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

cancer; monoclonal antibody; pregnancy; reproductive toxicity; transplacental transfer

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IBRATUMOMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PANITUMUMAB; RITUXIMAB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANHYDRAMNIOS; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONGESTIVE HEART FAILURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TARGETING; EDITORIAL; EYE CANCER; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY CANCER; LONG TERM EXPOSURE; LUNG CANCER; LYMPHOMA; MATERNAL CARE; MORNING STIFFNESS; MOTHER FETUS RELATIONSHIP; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGOHYDRAMNIOS; ONCOGENE; OVARY CANCER; PASSIVE IMMUNIZATION; PREGNANCY; RISK ASSESSMENT; SPONTANEOUS ABORTION; SUBRETINAL NEOVASCULARIZATION; UTERINE CERVIX CANCER; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FETAL DEVELOPMENT; HUMANS; PLACENTAL CIRCULATION; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; TOXICITY TESTS;

EID: 78049420497     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.77     Document Type: Editorial

References (64)

1. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur. J. Cancer 42(2), 126-140 (2006).
2. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 7(4), 279-287 (2002).
3. Azim HA Jr, Peccatori FA. Treatment of cancer during pregnancy: the need for tailored strategies. J. Clin. Oncol. 28(18), e302-e303; author reply e304 (2010).
4. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy Lancet Oncol. 5(5), 283-291 (2004).
5. Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy Part II: hematological tumors. Cancer Treat Rev. 36(2), 110-121 (2010).
6. Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy Part I: solid tumors. Cancer Treat Rev. 36(2), 101-109 (2010).
7. Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 8(8), 738-743 (2007).
8. Mix E, Goertsches R, Zett UK. Immunoglobulins-basic considerations. J. Neurol. 253(Suppl. 5), V9-V17 (2006).
9. Simister NE. Placental transport of immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
10. Congy-Jolivet N, Probst A, Watier H, Thibault G. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 64(3), 226-233 (2007).
11. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev. Reprod. 4(2), 81-89 (1999).
12. Takizawa T, Anderson CL, Robinson JM. A novel FcγR-defned, IgG-containing organelle in placental endothelium. J. Immunol. 175(4), 2331-2339 (2005).
13. Malek A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21(24), 3362-3364 (2003).
14. Israel EJ, Simister N, Freiberg E, Caplan A, Walker WA. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology 79(1), 77-81 (1993).
15. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B. Dev. Reprod. Toxicol. 86(4), 328-344 (2009).
16. Gurevich P, Elhayany A, Ben-Hur H et al. An immunohistochemical study of the secretory immune system in human fetal membranes and decidua of the frst trimester of pregnancy. Am. J. Reprod. Immunol. 50(1), 13-19 (2003).
17. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Diversity 10(4), 515-527 (2006).
18. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380(6573), 439-442 (1996).
19. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 14(3), 170-177 (2008).
20. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm. Res. 55, 15-35; discussion 35-16 (2000).
21. Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem. 109(4), 257-265 (2007).
22. Pauli SA, Tang H, Wang J et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146(3), 1301-1311 (2005)
23. Cheung CY Vascular endothelial growth factor activation of intramembranous absorption: a critical pathway for amniotic fuid volume regulation. J. Soc. Gynecol. Invest. 11(2), 63-74 (2004).
24. Leck IM, Millar EL. Incidence of malformations since the introduction of thalidomide. Br. Med. J. 2(5296), 16-20 (1962).
25. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 59(12), 1489-1499 (2000).
26. Demir R, Kayisli UA, Seval Y et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25(6), 560-572 (2004).
27. Patyna S, Haznedar J, Morris D et al. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res. 86(3), 204-213 (2009).
28. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev. 6(8), 465-477 (2009).
29. Berkane N. [Gestational hypertensions: defnitions and consequences in outcome of pregnancy]. Ann. Fr. Anesth. Reanim. 29(3), e1-e6 (2010).
30. Wu Z, Huang J, Sadda S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann. Acad. Med. Singapore 39(2), 143-145 (2010).
31. Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfn and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye 23(6), 1479 (2009).
32. Petrou P, Georgalas I, Giavaras G et al. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmologica 88(4), e136 (2010).
33. Azim H, Azim HA Jr. Targeting Her-2/neu in breast cancer: as easy as this! Oncology 74(3-4), 150-157 (2008).
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl. J. Med. 353(16), 1659-1672 (2005).
35. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
36. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116(4), 791-798 (2010).
37. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555), 394-398 (1995).
38. Negro A, Brar BK, Gu Y et al. ErbB2 is required for G protein-coupled receptor signaling in the heart. Proc. Natl Acad. Sci. USA 103(43), 15889-15893 (2006).
39. Azim H, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 35(7), 633-638 (2009).
40. Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy J. Clin. Oncol. 24(2), 321-322 (2006).
41. Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol. 105(3), 642-643 (2005).
42. Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin. Breast Cancer 6(4), 354-356 (2005).
43. Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy Lancet Oncol. 8(1), 79-81 (2007).
44. Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Favorable pregnancy outcome following trastuzumab (Herceptin) use during pregnancy-case report and updated literature review. Reprod. Toxicol. 23(4), 611-613 (2007).
45. Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy Obstet Gynecol. 110(2 Pt 2), 507-510 (2007).
46. Witzel ID, Muller V, Harps E, Janicke F, Dewit M. Trastuzumab in pregnancy associated with poor fetal outcome. Ann. Oncol. 19(1), 191-192 (2008).
47. Berveiller P, Mir O, Sauvanet E, Antoine EC, Goldwasser F. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod. Toxicol. 25(2), 286-288 (2008).
48. Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J. Clin. Oncol. 26(9), 1567-1569 (2008).
49. Weber-Schoendorfer C, Schaefer C. Trastuzumb exposure during pregnancy. Reprod. Toxicol. 25(3), 390-391; author reply 392 (2008).
50. Azim HA Jr, Peccatori FA, Liptrott SJ, Catania C, Goldhirsch A. Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev. 6(6), 367-370 (2009).
51. Goodyer MJ, Ismail JR, O'Reilly SP et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J. 2, 9329 (2009).
52. Warraich Q, Smith N. Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J. Obstet. Gynaecol. 29(2), 147-148 (2009).
53. Beale JM, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am. J. Obstet. Gynecol. 201(1), e13-e14 (2009).
54. Kokai Y, Cohen JA, Drebin JA, Greene MI. Stage-and tissue-specifc expression of the neu oncogene in rat development. Proc. Natl Acad. Sci. USA 84(23), 8498-8501 (1987).
55. Coiffer B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
56. van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study J. Clin. Oncol. 28(17), 2853-2858 (2010).
57. Cordeiro A, Machado AI, Borges A, Alves MJ, Frade MJ. Burkitt's lymphoma related to Epstein-Barr virus infection during pregnancy. Arch. Gynecol. Obstet. 280(2), 297-300 (2009).
58. Rey J, Coso D, Roger V et al. Rituximab combined with chemotherapy for lymphoma during pregnancy. Leukemia Res. 33(3), e8-e9 (2009).
59. Decker M, Rothermundt C, Hollander G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy Lancet Oncol. 7(8), 693-694 (2006).
60. Magloire LK, Pettker CM, Buhimschi CS, Funai EF. Burkitt's lymphoma of the ovary in pregnancy. Obstet. Gynecol. 108(3 Pt 2), 743-745 (2006).
61. Friedrichs B, Tiemann M, Salwender H et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91(10), 1426-1427 (2006).
62. Herold M, Schnohr S, Bittrich H. Effcacy and safety of a combined rituximab chemotherapy during pregnancy. J. Clin. Oncol. 19(14), 3439 (2001).
63. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the frst trimester of pregnancy: a case history Eur. J. Hematol. 72(4), 292-295 (2004).
64. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol. 2008, 271363 (2008).